Legal Notices

Terms and Conditions

BY USING THIS SITE YOU ACKNOWLEDGE THAT TERCICA, INC., IS PROVIDING THE MATERIAL FOR INFORMATIONAL PURPOSES ONLY AND THAT NEITHER TERCICA, INC., NOR THEIR AGENTS, AFFILIATES, PARTNERS, OR LICENSORS ARE PROVIDING THE MATERIALS TO YOU FOR THE PURPOSES OF GIVING YOU MEDICAL ADVICE. YOU SHOULD NOT RELY ON THE MATERIALS IN DECIDING ON A TREATMENT PLAN, DRUG USAGE, OR ANY OTHER MEDICAL ADVICE REGARDING THE MATERIALS, AND TERCICA, INC., AND THEIR LICENSORS STRONGLY URGE THAT YOU CONSULT WITH A PHYSICIAN IN CONNECTION WITH ANY AND ALL TREATMENT OPTIONS THAT MAY BE AVAILABLE TO YOU.
BY USING THIS WEBSITE, YOU ACCEPT THE INFORMATION, PRODUCTS, AND SERVICES PROVIDED HEREIN "AS IS." TERCICA, INC., MAKES NO EXPRESS OR IMPLIED WARRANTY REGARDING THE ACCURACY, CONTENT, COMPLETENESS, RELIABILITY, OPERABILITY, OR LEGALITY OF INFORMATION CONTAINED WITHIN THIS WEB SITE, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF PROPRIETARY RIGHTS.

IN NO EVENT SHALL TERCICA, INC., OR ITS AGENTS, AFFILIATES, PARTNERS, OR LICENSORS BE LIABLE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES OR ANY DAMAGES WHATSOEVER RESULTING FROM LOSS RELATED TO THE USE OF OUR WEB SITES, WHETHER IN AN ACTION OF CONTRACT, BREACH OF WARRANTY, NEGLIGENCE, OR OTHER TORTIOUS ACTION ARISING OUT OF OR IN CONNECTION WITH THE USE OF THE MATERIALS CONTAINED ON THIS SITE.

Important Safety Information

Somatuline^® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline^® Depot (lanreotide) Injection may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline^® Depot (lanreotide) Injection 60mg.

There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline^® Depot (lanreotide) Injection should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline^® Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline^® Depot (lanreotide) Injection may reduce the intestinal absorption of co-administered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.

Please see Full Prescribing Information for additional important information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

REGISTER

Register today to view and participate in our Webinar series.